Asia Commercial Bank [ACB VN]

29 January 2024

BUY

TP upside +10% Close 29 Jan 2024

Price VND 25,950 12M Target VND 28,517

Share price performance relative to VNI



| Market cap | US\$4.2 bn |
|--------------------------|------------|
| 6M avg. daily turnover | US\$9.2 mn |
| Outstanding shares | 3,884 mn |
| Free float | 90.0% |
| FINI ownership | 30.0% |
| Major shareholders | 33% |
| 2024E Asset/equity (x) | 9.1x |
| 2024E P/E (x) | 5.4x |
| 2024E P/B (x) | 1.1x |
| FOL remaining room | 0.0% |
| 2024E dividend yield (%) | 3.8% |
| | |

Source: FiinPro, Yuanta Vietnam

| ACB's 4Q23 Results | 4Q23 | % QoQ | % YoY | |
|--------------------------------------|-------|----------|-----------|--|
| NII (VND bn) | 6,290 | 1% | -3% | |
| Net Fee Inc.(VND bn) | 727 | -5% | -22% | |
| Other non-II (VND bn) | 1,375 | 5% | 240% | |
| Adj. TOI (VND bn) | 8,392 | 1% | 8% | |
| Opex (VND bn) | 3,013 | 5% | -26% | |
| Provision (VND bn) | 322 | -38% | 28% | |
| PATMI (VND bn) | 4,006 | -1% | 40% | |
| NPL (%) | 1.21% | 1 bps | 47bps | |
| LLR (%) | 91% | -3ppt | -68ppt | |
| CASA (%) | 22.0% | 1.4ppt | 20bps | |
| CAR | 12.5% | | | |
| ST funds for MLT loans | 17.3% | (vs. cap | of 30.0%) | |
| LDR | 78.1% | (vs. cap | of 85.0%) | |
| Source: Company Data, Yuanta Vietnam | | | | |

Research Analyst:

Tanh Tran

+84 28 3622 6868 ext 3874 tanh.tran@yuanta.com.vn

Bloomberg code: YUTA

Analyst Meeting Takeaways Investment gains lift 4Q earnings

ACB posted 4Q23 PATMI of VND 4.0 tn (-1% QoQ/+40% YoY). 2023 PATMI was VND16 tn (+17% YoY), completing 103% of our forecast.

Details

Credit increased by 17.9% in 2023, mainly from corporate clients $(+19\% \, \text{YoY})$, followed by consumers $(+18\% \, \text{YoY})$, and SMEs $(+16\% \, \text{YoY})$. 98% of ACB's loans are secured with an average LTV of 55%. ACB disclosed that its 2024 credit growth quota is $+16.1\% \, \text{YoY}$.

4Q23 net interest income was VND6.3 tn (+1% QoQ/ but -3% YoY). ACB reported NIM of 3.76% (-38bp YoY); however, the bank expects NIM to recover to about 4.0% in 2024 on lower cost of funds (COF). ACB's COF was 3.6% in 4Q23 (-70bps vs 3Q23 & -1.1ppt vs 2Q23).

4Q23 net fee income decreased by -5% QoQ and -22% YoY, largely attributable to lower banca sales.

Investment gains (mostly on government bonds) were the key earnings driver at VND1.3tn (+42% QoQ and vs. losses of -VND113 bn in 4Q22).

Opex was VND3.0 tn (+5% QoQ/ but -26% YoY) in 4Q23. The bank reported full-year CIR of 33% (-7ppt YoY) for 2023, and it expects CIR to be around 35% in 2024.

4Q23 provisioning was VND322 bn (-38% QoQ/ but +28% YoY), and total 2023 provisioning was VND1.8 tn (up 25x vs. 2022).

NPL ratio was 1.21% (+1bps QoQ/+47bps YoY) and LLR ratio decreased to 91% (-3ppt QoQ/-68ppt YoY) due to the higher denominator. ACB expects its NPL ratio to decline to c.1.0% in 2024.

Cash dividend plan: 1,000 VND/share in 2024.

Our view

Investment gains fail to inspire, but we think that net interest income will re-emerge as the key earnings driver in 2024, given reduced COF. We forecast ACB's 2024E PATMI to increase by +24% YoY.

CASA recovery is a positive. ACB's CASA deposit ratio has trended up since 2Q23 and it ranks among the top 4 banks. We expect the reduced term deposit rates to help boost CASA deposits in 2024.

Asset quality remains strong. ACB maintains healthy NPL and LLR ratios with a robust CAR of 12.5%.

Maintain BUY. ACB's shares trade at 1.1x 2024E P/B, slightly above the sector median of 1.0x. This valuation is still quite cheap in our opinion given ACB's solid balance sheet, superior operating efficiency, and 2024E ROE of 24% vs. the sector's 20%.

ACB's stock has increased by 15% since <u>our last update of Aug 23</u>. We remain Overweight the banks with ACB as a top pick in the sector. However, we foresee a minor near-term correction ahead of Tet.

ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ARE LOCATED IN APPENDIX A.

Yuanta does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Appendix A: Important Disclosures

Analyst Certification

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

Ratings Definitions

BUY: We have a positive outlook on the stock based on our expected absolute or relative return over the investment period. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile. We recommend investors add to their position.

HOLD-Outperform: In our view, the stock's fundamentals are relatively more attractive than peers at the current price. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile.

HOLD-Underperform: In our view, the stock's fundamentals are relatively less attractive than peers at the current price. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile.

SELL: We have a negative outlook on the stock based on our expected absolute or relative return over the investment period. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile. We recommend investors reduce their position.

Under Review: We actively follow the company, although our estimates, rating and target price are under review.

Restricted: The rating and target price have been suspended temporarily to comply with applicable regulations and/or Yuanta policies.

Note: Yuanta research coverage with a Target Price is based on an investment period of 12 months. Greater China Discovery Series coverage does not have a formal 12 month Target Price and the recommendation is based on an investment period specified by the analyst in the report.

Global Disclaimer

© 2023 Yuanta. All rights reserved. The information in this report has been compiled from sources we believe to be reliable, but we do not hold ourselves responsible for its completeness or accuracy. It is not an offer to sell or solicitation of an offer to buy any securities. All opinions and estimates included in this report constitute our judgment as of this date and are subject to change without notice.

This report provides general information only. Neither the information nor any opinion expressed herein constitutes an offer or invitation to make an offer to buy or sell securities or other investments. This material is prepared for general circulation to clients and is not intended to provide tailored investment advice and does not take into account the individual financial situation and objectives of any specific person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any securities, investments or investment strategies discussed or recommended in this report. The information contained in this report has been compiled from sources believed to be reliable but no representation or warranty, express or implied, is made as to its accuracy, completeness or correctness. This report is not (and should not be construed as) a solicitation to act as securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on such business in that jurisdiction.

Yuanta research is distributed in the United States only to Major U.S. Institutional Investors (as defined in Rule 15a–6 under the Securities Exchange Act of 1934, as amended and SEC staff interpretations thereof). All transactions by a US person in the securities mentioned in this report must be effected through a registered broker–dealer under Section 15 of the Securities Exchange Act of 1934, as amended. Yuanta research is distributed in Taiwan by Yuanta Securities Investment Consulting. Yuanta research is distributed in Hong Kong by Yuanta Securities (Hong Kong) Co. Limited, which is licensed in Hong Kong by the Securities and Futures Commission for regulated activities, including Type 4 regulated activity (advising on securities). In Hong Kong, this research report may not be redistributed, retransmitted or disclosed, in whole or in part or and any form or manner, without the express written consent of Yuanta Securities (Hong Kong) Co. Limited.

Taiwan persons wishing to obtain further information on any of the securities mentioned in this publication should contact:

Attn: Research Yuanta Securities Investment Consulting 4F, 225, Section 3 Nanking East Road, Taipei 104 Taiwan

Hong Kong persons wishing to obtain further information on any of the securities mentioned in this publication should contact:

Attn: Research Yuanta Securities (Hong Kong) Co. Ltd 23/F, Tower 1, Admiralty Centre 18 Harcourt Road, Hong Kong

Korean persons wishing to obtain further information on any of the securities mentioned in this publication should contact:

Head Office Yuanta Securities Building Euljiro 76 Jung-gu Seoul, Korea 100-845 Tel: +822 3770 3454

Indonesia persons wishing to obtain further information on any of the securities mentioned in this publication should contact:

Attn: Research PT YUANTA SECURITIES INDONESIA (A member of the Yuanta Group) Equity Tower, 10th Floor Unit EFGH SCBD Lot 9 Jl. Jend. Sudirman Kav. 52-53 Tel: (6221) - 5153608 (General)

Thailand persons wishing to obtain further information on any of the securities mentioned in this publication should contact:

Research department Yuanta Securities (Thailand) 127 Gaysorn Tower, 16th floor Ratchadamri Road, Pathumwan Bangkok 10330

Vietnam persons wishing to obtain further information on any of the securities mentioned in this publication should contact:

Research department Yuanta Securities (Vietnam) 4th Floor, Saigon Centre Tower 1, 65 Le Loi Boulevard, Ben Nghe Ward, District 1, HCMC, Vietnam

YUANTA SECURITIES VIETNAM OFFICE

Head office: 4th Floor, Saigon Centre, Tower 1, 65 Le Loi Boulevard, Ben Nghe Ward, District 1, HCMC, Vietnam

Matthew Smith, CFA

Head of Research

Tel: +84 28 3622 6868 (ext. 3815) matthew.smith@yuanta.com.vn

Tanh Tran

Analyst (Banks)

Tel: +84 28 3622 6868 (ext. 3874)

tanh.tran@yuanta.com.vn

Di Luu

Analyst (Consumer)

Tel: +84 28 3622 6868 (ext. 3845)

di.luu@yuanta.com.vn

Institutional Sales

Lawrence Heavey

Head of Institutional Sales

Tel: +84 28 3622 6868 (ext. 3835) lawrence.heavey@yuanta.com.vn

Dat Bui

Sales Trader

Tel: +84 28 3622 6868 (ext. 3941)

dat.bui@yuanta.com.vn

Binh Truong

Deputy Head of Research (O&G, Energy) Tel: +84 28 3622 6868 (ext. 3845)

binh.truong@yuanta.com.vn

Tam Nguyen

Analyst (Property)

Tel: +84 28 3622 6868 (ext. 3874)

tam.nguyen@yuanta.com.vn

An Nguyen

Assistant Analyst

Tel: +84 28 3622 6868 (ext. 3845)

an.nguyen@yuanta.com.vn

Anh Nguyen

Sales Trader Supervisor

Tel: +84 28 3622 6868 (ext. 3909) anh.nguyen2@yuanta.com.vn

Hien Le

Sales Trader

Tel: +84 28 3622 6868 hien.le@yuanta.com.vn

Vi Truong

Sales Trader

Tel: +84 28 3622 6868 (ext. 3940)

vi.truong@yuanta.com.vn